HUS2200033I1 - CGRP receptor antagonisták - Google Patents

CGRP receptor antagonisták

Info

Publication number
HUS2200033I1
HUS2200033I1 HUS2200033C HUS2200033C HUS2200033I1 HU S2200033 I1 HUS2200033 I1 HU S2200033I1 HU S2200033 C HUS2200033 C HU S2200033C HU S2200033 C HUS2200033 C HU S2200033C HU S2200033 I1 HUS2200033 I1 HU S2200033I1
Authority
HU
Hungary
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Application number
HUS2200033C
Other languages
English (en)
Hungarian (hu)
Original Assignee
08543
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2200033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 08543 filed Critical 08543
Publication of HUS2200033I1 publication Critical patent/HUS2200033I1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUS2200033C 2009-10-14 2022-07-18 CGRP receptor antagonisták HUS2200033I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25147709P 2009-10-14 2009-10-14
EP10768347.6A EP2488512B1 (en) 2009-10-14 2010-10-13 CGRP receptor antagonists

Publications (1)

Publication Number Publication Date
HUS2200033I1 true HUS2200033I1 (hu) 2022-08-28

Family

ID=43242489

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS2200033C HUS2200033I1 (hu) 2009-10-14 2022-07-18 CGRP receptor antagonisták

Country Status (35)

Country Link
US (2) US8314117B2 (enExample)
EP (1) EP2488512B1 (enExample)
JP (3) JP5836279B2 (enExample)
KR (3) KR101755742B1 (enExample)
CN (1) CN102656159B (enExample)
AR (2) AR078638A1 (enExample)
AU (1) AU2010306954B2 (enExample)
BR (1) BR112012008828B1 (enExample)
CA (2) CA2968176C (enExample)
CL (1) CL2012000925A1 (enExample)
CO (1) CO6460732A2 (enExample)
CY (1) CY2022023I1 (enExample)
DK (1) DK2488512T3 (enExample)
EA (1) EA020409B1 (enExample)
ES (1) ES2441192T3 (enExample)
FR (1) FR22C1044I2 (enExample)
HR (1) HRP20140111T1 (enExample)
HU (1) HUS2200033I1 (enExample)
IL (1) IL219120A (enExample)
LT (1) LTC2488512I2 (enExample)
LU (1) LUC00272I2 (enExample)
MX (1) MX2012004182A (enExample)
NL (1) NL301187I2 (enExample)
NO (1) NO2022033I1 (enExample)
NZ (1) NZ599281A (enExample)
PE (1) PE20121137A1 (enExample)
PL (1) PL2488512T3 (enExample)
PT (1) PT2488512E (enExample)
RS (1) RS53149B (enExample)
SI (1) SI2488512T1 (enExample)
SM (1) SMT201400019B (enExample)
TN (1) TN2012000139A1 (enExample)
TW (1) TWI465448B (enExample)
WO (1) WO2011046997A1 (enExample)
ZA (1) ZA201203452B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) * 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
HUE034936T2 (hu) * 2012-02-27 2018-03-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B-]piridin-9-il-4- (2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-IL)piperidin-1-karboxilát, hemiszulfát só
WO2013169563A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TW201718574A (zh) * 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
KR20200135465A (ko) 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
CN114805206B (zh) * 2021-01-27 2025-01-14 奥锐特药业(天津)有限公司 高光学纯度瑞美吉泮中间体的工业化制备方法
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び/又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
CN116478211B (zh) * 2022-04-19 2023-10-24 石家庄迪斯凯威医药科技有限公司 一种新型cgrp受体拮抗剂及其用途
CN115060824B (zh) * 2022-06-14 2024-03-12 浙江宏元药业股份有限公司 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法
CN117466893A (zh) * 2022-07-29 2024-01-30 熙源安健医药(上海)有限公司 吡啶并环庚烷类衍生物及其制备方法和用途
CN115677694A (zh) * 2022-11-30 2023-02-03 南通常佑药业科技有限公司 一种瑞美吉泮的合成方法
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
CN116768938B (zh) * 2023-05-17 2025-11-11 南京艾德凯腾生物医药有限责任公司 一种铁催化剂及瑞美吉泮中间体的制备方法
WO2025061177A1 (zh) * 2023-09-21 2025-03-27 成都康弘药业集团股份有限公司 一种治疗cgrp相关障碍的小分子药物
CN117486798B (zh) * 2023-12-21 2025-02-07 南京威凯尔生物医药科技有限公司 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor
CN119707808B (zh) * 2024-12-23 2025-12-05 上海彩迩文生化科技有限公司 一种制备cgrp受体拮抗剂中间体的方法
CN119977885A (zh) * 2025-04-15 2025-05-13 常州制药厂有限公司 (5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇L-酒石酸盐及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1726590A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd CYCLOALKANOPYRIDINDERIVAT
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Cgrp 수용체 길항제
US20060084708A1 (en) 2004-10-14 2006-04-20 Bayer Materialscience Llc Rigid foams with good insulation properties and a process for the production of such foams
JP2008517916A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Cgrp受容体拮抗薬
CN101421267B (zh) 2006-04-10 2011-10-19 默沙东公司 制备吡啶杂环cgrp拮抗剂中间体的方法
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists

Also Published As

Publication number Publication date
AU2010306954A1 (en) 2012-05-03
LTC2488512I2 (enExample) 2025-03-10
NZ599281A (en) 2013-01-25
TN2012000139A1 (en) 2013-09-19
HK1169390A1 (en) 2013-01-25
LTPA2022516I1 (enExample) 2022-08-25
RS53149B (sr) 2014-06-30
EP2488512B1 (en) 2013-11-27
TW201118096A (en) 2011-06-01
AR078638A1 (es) 2011-11-23
JP2017125054A (ja) 2017-07-20
PE20121137A1 (es) 2012-08-30
AR110069A2 (es) 2019-02-20
BR112012008828B1 (pt) 2021-11-23
SMT201400019B (it) 2014-05-07
ZA201203452B (en) 2014-10-29
PL2488512T3 (pl) 2014-04-30
WO2011046997A1 (en) 2011-04-21
EP2488512A1 (en) 2012-08-22
CN102656159B (zh) 2015-07-01
CA2777518A1 (en) 2011-04-21
MX2012004182A (es) 2012-05-29
JP2013508281A (ja) 2013-03-07
KR20180080343A (ko) 2018-07-11
FR22C1044I1 (fr) 2022-09-30
CL2012000925A1 (es) 2012-08-31
EA020409B1 (ru) 2014-10-30
KR20170081737A (ko) 2017-07-12
KR101990755B1 (ko) 2019-06-18
US20130053570A1 (en) 2013-02-28
FR22C1044I2 (fr) 2023-11-17
JP2015163625A (ja) 2015-09-10
CY2022023I2 (el) 2023-01-05
JP6258537B2 (ja) 2018-01-10
ES2441192T3 (es) 2014-02-03
HRP20140111T1 (hr) 2014-03-14
JP6109874B2 (ja) 2017-04-05
NL301187I2 (nl) 2022-08-04
SI2488512T1 (sl) 2014-02-28
BR112012008828A2 (pt) 2020-09-15
IL219120A0 (en) 2012-06-28
KR101755742B1 (ko) 2017-07-07
US20110251223A1 (en) 2011-10-13
CA2777518C (en) 2017-07-04
CY2022023I1 (el) 2023-01-05
DK2488512T3 (en) 2014-02-24
CA2968176A1 (en) 2011-04-21
KR101875353B1 (ko) 2018-07-05
KR20120087940A (ko) 2012-08-07
CO6460732A2 (es) 2012-06-15
CN102656159A (zh) 2012-09-05
NO2022033I1 (no) 2022-07-22
JP5836279B2 (ja) 2015-12-24
AU2010306954B2 (en) 2016-05-26
EA201270561A1 (ru) 2012-12-28
US8314117B2 (en) 2012-11-20
PT2488512E (pt) 2014-02-24
LUC00272I2 (enExample) 2025-05-12
CA2968176C (en) 2019-11-26
TWI465448B (zh) 2014-12-21
IL219120A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
CY2023022I1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
EP2350060A4 (en) Melanocortin receptor AGONISTS
SMT201600078B (it) Antagonista del recettore per cgrp
PT3091012T (pt) Antagonistas do receptor ccr2 e suas utilizações
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0817835A2 (pt) Antagonistas cgrp
BRPI0918004A2 (pt) antagonistas de glucagon
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
EP2654421A4 (en) CONDENSED HETEROCYCLIC INDAN CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
SMT201500293B (it) Antagonisti del recettore toll-like 3
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
EP2271346A4 (en) MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
EP2458991A4 (en) RADIOACTIVELY MARKED CGRP ANTAGONISTS
BRPI1014668A2 (pt) antagonistas ccr3 de arilsulfonamida
EP2340025A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister